Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has made a significant investment in Neuro42 Inc., a US-based company specialising in advanced portable MRI systems. This move aims to transform neuroimaging and interventions with cutting-edge technology that brings advanced diagnostic and therapeutic solutions directly to patients’ bedsides. Neuro42 is at the forefront […]
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 inhibitor, NB-4746. This first-in-class, oral, brain-penetrating inhibitor offers broad therapeutic potential across a range of neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), and […]
ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal to develop a short-term treatment for mild traumatic brain injury (mTBI) or concussion. Neuronasal’s concussion treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute concussion. N-acetylcysteine has been safely used for […]